0001171843-20-003141.txt : 20200430 0001171843-20-003141.hdr.sgml : 20200430 20200430172947 ACCESSION NUMBER: 0001171843-20-003141 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20200430 DATE AS OF CHANGE: 20200430 GROUP MEMBERS: 2004597 ONTARIO INC. GROUP MEMBERS: 2004598 ONTARIO INC. GROUP MEMBERS: 2526386 ONTARIO INC. GROUP MEMBERS: DAMIAN LAMB GROUP MEMBERS: GENESYS CAPITAL MANAGEMENT (FUND III) INC. GROUP MEMBERS: GENESYS CAPITAL MANAGEMENT INC. GROUP MEMBERS: GENESYS GENERAL PARTNER (FUND III) INC. GROUP MEMBERS: GENESYS GENERAL PARTNER (FUND III) LP GROUP MEMBERS: GENESYS GENERAL PARTNER INC. GROUP MEMBERS: GENESYS GENERAL PARTNER LP GROUP MEMBERS: GENESYS VENTURES III LP GROUP MEMBERS: JAMIE STIFF GROUP MEMBERS: KELLY HOLMAN SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Profound Medical Corp. CENTRAL INDEX KEY: 0001628808 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 000000000 STATE OF INCORPORATION: A6 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-91344 FILM NUMBER: 20837013 BUSINESS ADDRESS: STREET 1: 2400 SKYMARK AVENUE, UNIT 6 CITY: MISSISSAUGA STATE: A6 ZIP: L4W 5K5 BUSINESS PHONE: 647-476-1350 MAIL ADDRESS: STREET 1: 2400 SKYMARK AVENUE, UNIT 6 CITY: MISSISSAUGA STATE: A6 ZIP: L4W 5K5 FORMER COMPANY: FORMER CONFORMED NAME: Profound Medical Inc. DATE OF NAME CHANGE: 20141222 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Genesys Ventures II LP CENTRAL INDEX KEY: 0001806939 IRS NUMBER: 000000000 STATE OF INCORPORATION: A6 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: 123 FRONT STREET WEST SUITE 1503 STREET 2: PO BOX 34 CITY: TORONTO STATE: A6 ZIP: M5J 2M2 BUSINESS PHONE: (416) 598-4900 MAIL ADDRESS: STREET 1: 123 FRONT STREET WEST SUITE 1503 STREET 2: PO BOX 34 CITY: TORONTO STATE: A6 ZIP: M5J 2M2 SC 13G 1 sc13g_043020.htm SC 13G

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 13G

 

 

Under the Securities Exchange Act of 1934

(Amendment No. ________)*

 

 

Profound Medical Corp.

(Name of Issuer)

 

Common Shares

(Title of Class of Securities)

 

74319B502

(CUSIP Number)

 

December 31, 2019

(Date of Event which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐  Rule 13d-1(b)

☐  Rule 13d-1(c)

☒  Rule 13d-1(d)

 

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

CUSIP No. 74319B50213GPage 2 of 20 Pages

 

         
1.  

NAMES OF REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

 

Genesys Ventures II LP

    
2.  

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(see instructions)

(a)    ☐

(b)    ☒

    
3.  

SEC USE ONLY

 

    
4.  

CITIZENSHIP OR PLACE OF ORGANIZATION

 

 Ontario, Canada

    

 

         
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH		   5.  

SOLE VOTING POWER

 

Not applicable.

  6.  

SHARED VOTING POWER

 

910,087

  7.  

SOLE DISPOSITIVE POWER

 

Not applicable.

  8.  

SHARED DISPOSITIVE POWER

 

910,087

 

         
9.  

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

910,087

    
10.  

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

(see instructions)    ☐

 

    
11.  

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

7.68%(1)

    
12.  

TYPE OF REPORTING PERSON (see instructions)

 

PN

    
         

(1) Calculation of percentage of beneficial ownership as of December 31, 2019 is based on 11,852,749 common shares of Profound Medical Corp. (the “Common Shares”) outstanding as of December 31, 2019, as reported by Profound Medical Corp. in its Form 40-F filed with the United States Securities and Exchange Commission (the “Commission”) on March 3, 2020.

 

 

 

CUSIP No. 74319B50213GPage 3 of 20 Pages

 

         
1.  

NAMES OF REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

 

Genesys General Partner LP

    
2.  

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(see instructions)

(a)    ☐

(b)    ☒

    
3.  

SEC USE ONLY

 

    
4.  

CITIZENSHIP OR PLACE OF ORGANIZATION

 

 Ontario, Canada

    

 

         
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH		   5.  

SOLE VOTING POWER

 

Not applicable.

  6.  

SHARED VOTING POWER

 

910,087(1)

  7.  

SOLE DISPOSITIVE POWER

 

Not applicable.

  8.  

SHARED DISPOSITIVE POWER

 

910,087(1)

 

         
9.  

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

910,087(1)

    
10.  

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

(see instructions)    ☐

 

    
11.  

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

7.68%(2)

    
12.  

TYPE OF REPORTING PERSON (see instructions)

 

PN

    
         

(1) Includes 910,087 Common Shares held directly by Genesys Ventures II LP. Genesys General Partner LP is the general partner of Genesys Ventures II LP.

(2) Calculation of percentage of beneficial ownership as of December 31, 2019 is based on 11,852,749 Common Shares outstanding as of December 31, 2019, as reported by Profound Medical Corp. in its Form 40-F filed with the Commission on March 3, 2020.

 

 

 

CUSIP No. 74319B50213GPage 4 of 20 Pages

 

         
1.  

NAMES OF REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

 

Genesys General Partner Inc.

    
2.  

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(see instructions)

(a)    ☐

(b)    ☒

    
3.  

SEC USE ONLY

 

    
4.  

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Ontario, Canada

    

 

         
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH		   5.  

SOLE VOTING POWER

 

Not applicable.

  6.  

SHARED VOTING POWER

 

910,087(1)

  7.  

SOLE DISPOSITIVE POWER

 

Not applicable.

  8.  

SHARED DISPOSITIVE POWER

 

910,087(1)

 

         
9.  

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

910,087(1)

    
10.  

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

(see instructions)    ☐

 

    
11.  

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

7.68%(2)

    
12.  

TYPE OF REPORTING PERSON (see instructions)

 

CO

    
         

(1) Includes 910,087 Common Shares held directly by Genesys Ventures II LP. Genesys General Partner Inc. is the general partner of Genesys General Partner LP. Genesys General Partner LP is in turn the general partner of Genesys Ventures II LP.

(2) Calculation of percentage of beneficial ownership as of December 31, 2019 is based on 11,852,749 Common Shares outstanding as of December 31, 2019, as reported by Profound Medical Corp. in its Form 40-F filed with the Commission on March 3, 2020.

 

 

 

CUSIP No. 74319B50213GPage 5 of 20 Pages

 

         
1.  

NAMES OF REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

 

Genesys Capital Management Inc.

    
2.  

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(see instructions)

(a)    ☐

(b)    ☒

    
3.  

SEC USE ONLY

 

    
4.  

CITIZENSHIP OR PLACE OF ORGANIZATION

 

 Ontario, Canada

    

 

         
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH		   5.  

SOLE VOTING POWER

 

Not applicable.

  6.  

SHARED VOTING POWER

 

910,087(1)

  7.  

SOLE DISPOSITIVE POWER

 

Not applicable.

  8.  

SHARED DISPOSITIVE POWER

 

910,087(1)

 

         
9.  

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

910,087(1)

    
10.  

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

(see instructions)    ☐

 

    
11.  

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

7.68%(2)

    
12.  

TYPE OF REPORTING PERSON (see instructions)

 

CO

    
         

(1) Includes 910,087 Common Shares held directly by Genesys Ventures II LP. Genesys Capital Management Inc. is the sole shareholder of Genesys General Partner Inc. Genesys General Partner Inc. is in turn the general partner of Genesys General Partner LP. Genesys General Partner LP is in turn the general partner of Genesys Ventures II LP.

(2) Calculation of percentage of beneficial ownership as of December 31, 2019 is based on 11,852,749 Common Shares outstanding as of December 31, 2019, as reported by Profound Medical Corp. in its Form 40-F filed with the Commission on March 3, 2020.

 

 

 

CUSIP No. 74319B50213GPage 6 of 20 Pages

 

         
1.  

NAMES OF REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

 

Genesys Ventures III LP

    
2.  

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(see instructions)

(a)    ☐

(b)    ☒

    
3.  

SEC USE ONLY

 

    
4.  

CITIZENSHIP OR PLACE OF ORGANIZATION

 

 Ontario, Canada

    

 

         
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH		   5.  

SOLE VOTING POWER

 

Not applicable.

  6.  

SHARED VOTING POWER

 

422,727

  7.  

SOLE DISPOSITIVE POWER

 

Not applicable.

  8.  

SHARED DISPOSITIVE POWER

 

422,727

 

         
9.  

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

422,727

    
10.  

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

(see instructions)    ☐

 

    
11.  

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

3.57%(1)

    
12.  

TYPE OF REPORTING PERSON (see instructions)

 

PN

    
         

 

(1) Calculation of percentage of beneficial ownership as of December 31, 2019 is based on 11,852,749 Common Shares outstanding as of December 31, 2019, as reported by Profound Medical Corp. in its Form 40-F filed with the Commission on March 3, 2020.

 

 

 

CUSIP No. 74319B50213GPage 7 of 20 Pages

 

         
1.  

NAMES OF REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

 

Genesys General Partner (Fund III) LP

    
2.  

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(see instructions)

(a)    ☐

(b)    ☒

    
3.  

SEC USE ONLY

 

    
4.  

CITIZENSHIP OR PLACE OF ORGANIZATION

 

 Ontario, Canada

    

 

         
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH		   5.  

SOLE VOTING POWER

 

Not applicable.

  6.  

SHARED VOTING POWER

 

422,727(1)

  7.  

SOLE DISPOSITIVE POWER

 

Not applicable.

  8.  

SHARED DISPOSITIVE POWER

 

422,727(1)

 

         
9.  

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

422,727(1)

    
10.  

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

(see instructions)    ☐

 

    
11.  

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

3.57%(2)

    
12.  

TYPE OF REPORTING PERSON (see instructions)

 

PN

    
         

 

(1) Includes 422,727 Common Shares held directly by Genesys Ventures III LP. Genesys General Partner (Fund III) LP is the general partner of Genesys Ventures III LP.

(2) Calculation of percentage of beneficial ownership as of December 31, 2019 is based on 11,852,749 Common Shares outstanding as of December 31, 2019, as reported by Profound Medical Corp. in its Form 40-F filed with the Commission on March 3, 2020.

 

 

 

CUSIP No. 74319B50213GPage 8 of 20 Pages

 

         
1.  

NAMES OF REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

 

Genesys General Partner (Fund III) Inc.

    
2.  

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(see instructions)

(a)    ☐

(b)    ☒

    
3.  

SEC USE ONLY

 

    
4.  

CITIZENSHIP OR PLACE OF ORGANIZATION

 

 Ontario, Canada

    

 

         
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH		   5.  

SOLE VOTING POWER

 

Not applicable.

  6.  

SHARED VOTING POWER

 

422,727(1)

  7.  

SOLE DISPOSITIVE POWER

 

Not applicable.

  8.  

SHARED DISPOSITIVE POWER

 

422,727(1)

 

         
9.  

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

422,727(1)

    
10.  

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

(see instructions)    ☐

 

    
11.  

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

3.57%(2)

    
12.  

TYPE OF REPORTING PERSON (see instructions)

 

CO

    
         

 

(1) Includes 422,727 Common Shares held directly by Genesys Ventures III LP. Genesys General Partner (Fund III) Inc. is the general partner of Genesys General Partner (Fund III) LP. Genesys General Partner (Fund III) LP is in turn the general partner of Genesys Ventures III LP.

(2) Calculation of percentage of beneficial ownership as of December 31, 2019 is based on 11,852,749 Common Shares outstanding as of December 31, 2019, as reported by Profound Medical Corp. in its Form 40-F filed with the Commission on March 3, 2020.

 

 

 

 

 

CUSIP No. 74319B50213GPage 9 of 20 Pages

 

         
1.  

NAMES OF REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

 

Genesys Capital Management (Fund III) Inc.

    
2.  

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(see instructions)

(a)    ☐

(b)    ☒

    
3.  

SEC USE ONLY

 

    
4.  

CITIZENSHIP OR PLACE OF ORGANIZATION

 

 Ontario, Canada

    

 

         
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH		   5.  

SOLE VOTING POWER

 

Not applicable.

  6.  

SHARED VOTING POWER

 

422,727(1)

  7.  

SOLE DISPOSITIVE POWER

 

Not applicable.

  8.  

SHARED DISPOSITIVE POWER

 

422,727(1)

 

         
9.  

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

422,727(1)

    
10.  

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

(see instructions)    ☐

 

    
11.  

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

3.57%(2)

    
12.  

TYPE OF REPORTING PERSON (see instructions)

 

CO

    
         

 

(1) Includes 422,727 Common Shares held directly by Genesys Ventures III LP. Genesys Capital Management (Fund III) Inc. is the sole shareholder of Genesys General Partner (Fund III) Inc. Genesys General Partner (Fund III) Inc. is in turn the general partner of Genesys General Partner (Fund III) LP. Genesys General Partner (Fund III) LP is in turn the general partner of Genesys Ventures III LP.

(2) Calculation of percentage of beneficial ownership as of December 31, 2019 is based on 11,852,749 Common Shares outstanding as of December 31, 2019, as reported by Profound Medical Corp. in its Form 40-F filed with the Commission on March 3, 2020.

 

 

CUSIP No. 74319B50213GPage 10 of 20 Pages

 

         
1.  

NAMES OF REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

 

2004597 Ontario Inc.

    
2.  

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(see instructions)

(a)    ☐

(b)    ☒

    
3.  

SEC USE ONLY

 

    
4.  

CITIZENSHIP OR PLACE OF ORGANIZATION

 

 Ontario, Canada

    

 

         
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH		   5.  

SOLE VOTING POWER

 

Not applicable.

  6.  

SHARED VOTING POWER

 

422,727(1)

  7.  

SOLE DISPOSITIVE POWER

 

Not applicable.

  8.  

SHARED DISPOSITIVE POWER

 

422,727(1)

 

         
9.  

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

422,727(1)

    
10.  

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

(see instructions)    ☐

 

    
11.  

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

3.57%(2)

    
12.  

TYPE OF REPORTING PERSON (see instructions)

 

CO

    
         

 

(1) Includes 422,727 Common Shares held directly by Genesys Ventures III LP. 2004597 Ontario Inc. is a shareholder of Genesys Capital Management (Fund III) Inc. Genesys Capital Management (Fund III) Inc. is in turn the sole shareholder of Genesys General Partner (Fund III) Inc. Genesys General Partner (Fund III) Inc. is in turn the general partner of Genesys General Partner (Fund III) LP. Genesys General Partner (Fund III) LP is in turn the general partner of Genesys Ventures III LP.

(2) Calculation of percentage of beneficial ownership as of December 31, 2019 is based on 11,852,749 Common Shares outstanding as of December 31, 2019, as reported by Profound Medical Corp. in its Form 40-F filed with the Commission on March 3, 2020.

 

 

CUSIP No. 74319B50213GPage 11 of 20 Pages

 

         
1.  

NAMES OF REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

 

2004598 Ontario Inc.

    
2.  

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(see instructions)

(a)    ☐

(b)    ☒

    
3.  

SEC USE ONLY

 

    
4.  

CITIZENSHIP OR PLACE OF ORGANIZATION

 

 Ontario, Canada

    

 

         
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH		   5.  

SOLE VOTING POWER

 

Not applicable.

  6.  

SHARED VOTING POWER

 

422,727(1)

  7.  

SOLE DISPOSITIVE POWER

 

Not applicable.

  8.  

SHARED DISPOSITIVE POWER

 

422,727(1)

 

         
9.  

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

422,727(1)

    
10.  

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

(see instructions)    ☐

 

    
11.  

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

3.57%(2)

    
12.  

TYPE OF REPORTING PERSON (see instructions)

 

CO

    
         

 

(1) Includes 422,727 Common Shares held directly by Genesys Ventures III LP. 2004598 Ontario Inc. is a shareholder of Genesys Capital Management (Fund III) Inc. Genesys Capital Management (Fund III) Inc. is in turn the sole shareholder of Genesys General Partner (Fund III) Inc. Genesys General Partner (Fund III) Inc. is in turn the general partner of Genesys General Partner (Fund III) LP. Genesys General Partner (Fund III) LP is in turn the general partner of Genesys Ventures III LP.

(2) Calculation of percentage of beneficial ownership as of December 31, 2019 is based on 11,852,749 Common Shares outstanding as of December 31, 2019, as reported by Profound Medical Corp. in its Form 40-F filed with the Commission on March 3, 2020.

 

 

CUSIP No. 74319B50213GPage 12 of 20 Pages

 

         
1.  

NAMES OF REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

 

2526386 Ontario Inc.

    
2.  

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(see instructions)

(a)    ☐

(b)    ☒

    
3.  

SEC USE ONLY

 

    
4.  

CITIZENSHIP OR PLACE OF ORGANIZATION

 

 Ontario, Canada

    

 

         
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH		   5.  

SOLE VOTING POWER

 

Not applicable.

  6.  

SHARED VOTING POWER

 

422,727(1)

  7.  

SOLE DISPOSITIVE POWER

 

Not applicable.

  8.  

SHARED DISPOSITIVE POWER

 

422,727(1)

 

         
9.  

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

422,727(1)

    
10.  

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

(see instructions)    ☐

 

    
11.  

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

3.57%(2)

    
12.  

TYPE OF REPORTING PERSON (see instructions)

 

CO

    
         

 

(1) Includes 422,727 Common Shares held directly by Genesys Ventures III LP. 2526386 Ontario Inc. is a shareholder of Genesys Capital Management (Fund III) Inc. Genesys Capital Management (Fund III) Inc. is in turn the sole shareholder of Genesys General Partner (Fund III) Inc. Genesys General Partner (Fund III) Inc. is in turn the general partner of Genesys General Partner (Fund III) LP. Genesys General Partner (Fund III) LP is in turn the general partner of Genesys Ventures III LP.

(2) Calculation of percentage of beneficial ownership as of December 31, 2019 is based on 11,852,749 Common Shares outstanding as of December 31, 2019, as reported by Profound Medical Corp. in its Form 40-F filed with the Commission on March 3, 2020.

 

 

CUSIP No. 74319B50213GPage 13 of 20 Pages

 

         
1.  

NAMES OF REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

 

Kelly Holman

    
2.  

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(see instructions)

(a)    ☐

(b)    ☒

    
3.  

SEC USE ONLY

 

    
4.  

CITIZENSHIP OR PLACE OF ORGANIZATION

 

 Canada

    

 

         
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH		   5.  

SOLE VOTING POWER

 

Not applicable.

  6.  

SHARED VOTING POWER

 

422,727(1)

  7.  

SOLE DISPOSITIVE POWER

 

Not applicable.

  8.  

SHARED DISPOSITIVE POWER

 

422,727(1)

 

         
9.  

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

422,727(1)

    
10.  

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

(see instructions)    ☐

 

    
11.  

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

3.57%(2)

    
12.  

TYPE OF REPORTING PERSON (see instructions)

 

IN

    
         

 

(1) Includes 422,727 Common Shares held directly by Genesys Ventures III LP. Kelly Holman is the sole shareholder of 2004597 Ontario Inc. 2004597 Ontario Inc. is in turn a shareholder of Genesys Capital Management (Fund III) Inc. Genesys Capital Management (Fund III) Inc. is in turn the sole shareholder of Genesys General Partner (Fund III) Inc. Genesys General Partner (Fund III) Inc. is in turn the general partner of Genesys General Partner (Fund III) LP. Genesys General Partner (Fund III) LP in turn is the general partner of Genesys Ventures III LP.

(2) Calculation of percentage of beneficial ownership as of December 31, 2019 is based on 11,852,749 Common Shares outstanding as of December 31, 2019, as reported by Profound Medical Corp. in its Form 40-F filed with the Commission on March 3, 2020.

 

 

 

CUSIP No. 74319B50213GPage 14 of 20 Pages

 

         
1.  

NAMES OF REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

 

Damian Lamb

    
2.  

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(see instructions)

(a)    ☐

(b)    ☒

    
3.  

SEC USE ONLY

 

    
4.  

CITIZENSHIP OR PLACE OF ORGANIZATION

 

 Canada

    

 

         
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH		   5.  

SOLE VOTING POWER

 

Not applicable.

  6.  

SHARED VOTING POWER

 

422,727(1)

  7.  

SOLE DISPOSITIVE POWER

 

Not applicable.

  8.  

SHARED DISPOSITIVE POWER

 

422,727(1)

 

         
9.  

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

422,727(1)

    
10.  

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

(see instructions)    ☐

 

    
11.  

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

3.57%(2)

    
12.  

TYPE OF REPORTING PERSON (see instructions)

 

IN

    
         

 

(1) Includes 422,727 Common Shares held directly by Genesys Ventures III LP. Damian Lamb is the sole shareholder of 2004598 Ontario Inc. 2004598 Ontario Inc. is in turn a shareholder of Genesys Capital Management (Fund III) Inc. Genesys Capital Management (Fund III) Inc. is in turn the sole shareholder of Genesys General Partner (Fund III) Inc. Genesys General Partner (Fund III) Inc. is in turn the general partner of Genesys General Partner (Fund III) LP. Genesys General Partner (Fund III) LP is in turn the general partner of Genesys Ventures III LP.

(2) Calculation of percentage of beneficial ownership as of December 31, 2019 is based on 11,852,749 Common Shares outstanding as of December 31, 2019, as reported by Profound Medical Corp. in its Form 40-F filed with the Commission on March 3, 2020.

 

 

 

CUSIP No. 74319B50213GPage 15 of 20 Pages

 

         
1.  

NAMES OF REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

 

Jamie Stiff

    
2.  

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(see instructions)

(a)    ☐

(b)    ☒

    
3.  

SEC USE ONLY

 

    
4.  

CITIZENSHIP OR PLACE OF ORGANIZATION

 

 Canada

    

 

         
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH		   5.  

SOLE VOTING POWER

 

Not applicable.

  6.  

SHARED VOTING POWER

 

422,727(1)

  7.  

SOLE DISPOSITIVE POWER

 

Not applicable.

  8.  

SHARED DISPOSITIVE POWER

 

422,727(1)

 

         
9.  

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

422,727(1)

    
10.  

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

(see instructions)    ☐

 

    
11.  

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

3.57%(2)

    
12.  

TYPE OF REPORTING PERSON (see instructions)

 

IN

    
         

 

(1) Includes 422,727 Common Shares held directly by Genesys Ventures III LP. Jamie Stiff is the sole shareholder of 2526386 Ontario Inc. 2526386 Ontario Inc. is in turn a shareholder of Genesys Capital Management (Fund III) Inc. Genesys Capital Management (Fund III) Inc. is in turn the sole shareholder of Genesys General Partner (Fund III) Inc. Genesys General Partner (Fund III) Inc. is in turn the general partner of Genesys General Partner (Fund III) LP. Genesys General Partner (Fund III) LP in turn is the general partner of Genesys Ventures III LP.

(2) Calculation of percentage of beneficial ownership as of December 31, 2019 is based on 11,852,749 Common Shares outstanding as of December 31, 2019, as reported by Profound Medical Corp. in its Form 40-F filed with the Commission on March 3, 2020.

 

 

 

CUSIP No. 74319B50213GPage 16 of 20 Pages

 

Item 1.

 

  (a)

Name of Issuer

Profound Medical Corp.

     
  (b)

Address of Issuer’s Principal Executive Offices

2400 Skymark Avenue, Unit 6

Mississauga, Ontario L4W 5K5

     

Item 2.

 

  (a) Name of Person Filing
    (i) Genesys Ventures II LP.
     
    (ii) Genesys General Partner LP
     
    (iii) Genesys General Partner Inc.
     
    (iv) Genesys Capital Management Inc.
     
    (v) Genesys Ventures III LP
     
    (vi) Genesys General Partner (Fund III) LP
     
    (vii) Genesys General Partner (Fund III) Inc.
     
    (viii) Genesys Capital Management (Fund III) Inc.
     
    (ix) 2004597 Ontario Inc.
     
    (x) 2004598 Ontario Inc.
     
    (xi) 2526386 Ontario Inc.
     
    (xii) Kelly Holman
     
    (xiii) Damian Lamb
     
    (xiv) Jamie Stiff
     
  (b) Address of the Principal Office or, if none, residence
    (i) 123 Front Street West, Suite 1503, P.O. Box 34, Toronto, ON  M5J 2M2
     
    (ii) 123 Front Street West, Suite 1503, P.O. Box 34, Toronto, ON  M5J 2M2
     
    (iii) 123 Front Street West, Suite 1503, P.O. Box 34, Toronto, ON  M5J 2M2
     
    (iv) 123 Front Street West, Suite 1503, P.O. Box 34, Toronto, ON  M5J 2M2
     
    (v) 123 Front Street West, Suite 1503, P.O. Box 34, Toronto, ON  M5J 2M2
     
    (vi) 123 Front Street West, Suite 1503, P.O. Box 34, Toronto, ON  M5J 2M2
     
    (vii) 123 Front Street West, Suite 1503, P.O. Box 34, Toronto, ON  M5J 2M2
     
    (viii) 123 Front Street West, Suite 1503, P.O. Box 34, Toronto, ON  M5J 2M2
     
    (ix) 123 Front Street West, Suite 1503, P.O. Box 34, Toronto, ON  M5J 2M2
     
    (x) 123 Front Street West, Suite 1503, P.O. Box 34, Toronto, ON  M5J 2M2
     
    (xi) 123 Front Street West, Suite 1503, P.O. Box 34, Toronto, ON  M5J 2M2
     
    (xii) 123 Front Street West, Suite 1503, P.O. Box 34, Toronto, ON  M5J 2M2
     
    (xiii) 123 Front Street West, Suite 1503, P.O. Box 34, Toronto, ON  M5J 2M2
     
    (xiv) 123 Front Street West, Suite 1503, P.O. Box 34, Toronto, ON  M5J 2M2
     

 

 

CUSIP No. 74319B50213GPage 17 of 20 Pages

 

  (c) Citizenship
    (i) Ontario, Canada
     
    (ii) Ontario, Canada
     
    (ii) Ontario, Canada
     
    (iii) Ontario, Canada
     
    (iv) Ontario, Canada
     
    (v) Ontario, Canada
     
    (vi) Ontario, Canada
     
    (vii) Ontario, Canada
     
    (viii) Ontario, Canada
     
    (ix) Ontario, Canada
     
    (x) Ontario, Canada
     
    (xi) Ontario, Canada
     
    (xii) Canada
     
    (xiii) Canada
     
    (xiv) Canada
     
  (d) Title of Class of Securities
    Common Shares
     
  (e) CUSIP Number
    74319B502
     

Item 3.  If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

 

  (a) ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
       
  (b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
       
  (c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
       
  (d) ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
       
  (e) ☐ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
       
  (f) ☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
       
  (g) ☐ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
       
  (h) ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
       
  (i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
       
  (j) ☐ Group, in accordance with §240.13d-1(b)(1)(ii)(J).
       

 

 

CUSIP No. 74319B50213GPage 18 of 20 Pages

 

Item 4.  Ownership.

 

  (a) Amount Beneficially Owned: The responses of the Reporting Persons to Rows (5) through (11) of the cover pages of this Statement are incorporated herein by reference.

 

  (b) Percent of Class:  The responses of the Reporting Persons to Row (11) of the cover pages of this Statement are incorporated herein by reference.

 

  (c) Number of shares as to which the person has: The responses of the Reporting Persons to Rows (5) through (8) of the cover pages of this Statement are incorporated herein by reference.

 

Item 5.  Ownership of Five Percent or Less of a Class.

 

Not applicable.

 

Item 6.  Ownership of More than Five Percent on Behalf of Another Person.

 

Not applicable.

 

Item 7.  Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

 

Not applicable.

 

Item 8.  Identification and Classification of Members of the Group.

 

Not applicable.

 

Item 9.  Notice of Dissolution of Group.

 

Not applicable.

 

Item 10.  Certification.

 

Not applicable. 

 

EXHIBITS

 

1 Joint Filing Agreement, dated the date hereof, among the Reporting Persons.

  

 

CUSIP No. 74319B50213GPage 19 of 20 Pages

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

  Genesys Ventures II LP
   
   
  By: /s/ Damian Lamb
    Name: Damian Lamb
    Title: Authorized Signatory

 

 

  Genesys General Partner LP
   
   
  By: /s/ Damian Lamb
    Name: Damian Lamb
    Title: Authorized Signatory

 

  Genesys General Partner Inc.
   
   
  By: /s/ Damian Lamb
    Name: Damian Lamb
    Title: Authorized Signatory

 

  Genesys Capital Management Inc.
   
   
  By: /s/ Damian Lamb
    Name: Damian Lamb
    Title: Authorized Signatory

 

  Genesys Ventures III LP
   
   
  By: /s/ Damian Lamb
    Name: Damian Lamb
    Title: Authorized Signatory

 

  Genesys General Partner (Fund III) LP
   
   
  By: /s/ Damian Lamb
    Name: Damian Lamb
    Title: Authorized Signatory

 

 

CUSIP No. 74319B50213GPage 20 of 20 Pages

 

  Genesys General Partner (Fund III) Inc.
   
   
  By: /s/ Damian Lamb
    Name: Damian Lamb
    Title: Authorized Signatory

 

  Genesys Capital Management (Fund III) Inc.
   
   
  By: /s/ Damian Lamb
    Name: Damian Lamb
    Title: Authorized Signatory

 

  2004597 Ontario Inc.
   
   
  By: /s/ Kelly Holman
    Name: Kelly Holman
    Title: Authorized Signatory
     
  2004598 Ontario Inc.
   
   
  By: /s/ Damian Lamb
    Name: Damian Lamb
    Title: Authorized Signatory

 

  2526386 Ontario Inc.
   
   
  By: /s/ Jamie Stiff
    Name: Jamie Stiff
    Title: Authorized Signatory

 

  Kelly Holman
   
   
  By: /s/ Kelly Holman
    Name: Kelly Holman

 

  Damian Lamb
   
   
  By: /s/ Damian Lamb
    Name: Damian Lamb

 

  Jamie Stiff
   
   
  By: /s/ Jamie Stiff
    Name: Jamie Stiff

 

 

 EX-1 2 exh_1.htm EXHIBIT 1

EXHIBIT 1

 

AGREEMENT OF JOINT FILING

 

Pursuant to Rule 13d-1(k)(1) of the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended, each of the undersigned agrees that the statement on Schedule 13G filed herewith shall be filed on behalf of each of the undersigned.

 

  Genesys Ventures II LP
   
   
  By: /s/ Damian Lamb
    Name: Damian Lamb
    Title: Authorized Signatory

 

  Genesys General Partner LP
   
   
  By: /s/ Damian Lamb
    Name: Damian Lamb
    Title: Authorized Signatory

 

  Genesys General Partner Inc.
   
   
  By: /s/ Damian Lamb
    Name: Damian Lamb
    Title: Authorized Signatory

 

  Genesys Capital Management Inc.
   
   
  By: /s/ Damian Lamb
    Name: Damian Lamb
    Title: Authorized Signatory

 

  Genesys Ventures III LP
   
   
  By: /s/ Damian Lamb
    Name: Damian Lamb
    Title: Authorized Signatory

 

  Genesys General Partner (Fund III) LP
   
   
  By: /s/ Damian Lamb
    Name: Damian Lamb
    Title: Authorized Signatory

 

  Genesys General Partner (Fund III) Inc.
   
   
  By: /s/ Damian Lamb
    Name: Damian Lamb
    Title: Authorized Signatory

 

  Genesys Capital Management (Fund III) Inc.
   
   
  By: /s/ Damian Lamb
    Name: Damian Lamb
    Title: Authorized Signatory

 

 

 

  2004597 Ontario Inc.
   
   
  By: /s/ Kelly Holman
    Name: Kelly Holman
    Title: Authorized Signatory
     
  2004598 Ontario Inc.
   
   
  By: /s/ Damian Lamb
    Name: Damian Lamb
    Title: Authorized Signatory

 

  2526386 Ontario Inc.
   
   
  By: /s/ Jamie Stiff
    Name: Jamie Stiff
    Title: Authorized Signatory

 

  Kelly Holman
   
   
  By: /s/ Kelly Holman
    Name: Kelly Holman

 

  Damian Lamb
   
   
  By: /s/ Damian Lamb
    Name: Damian Lamb

 

  Jamie Stiff
   
   
  By: /s/ Jamie Stiff
    Name: Jamie Stiff